ALCEDIAG and SYNLAB join forces in Europe to fight diagnostic delay of bipolar disorder with the EDIT-B™ test
An estimated 2.3% of the European population is affected by bipolar disorder (BD), a largely underestimated figure, since an average of 8-10 years passes between the appearance of symptoms and diagnosis
To date, the diagnosis of BD is based on a psychiatric clinical examination of the patient, made by a psychiatrist.
BD is so difficult to diagnose because it is often confused with depression. Misdiagnosed patients may receive inappropriate treatment, which may even worsen their health condition.
To significantly reduce this diagnosis wondering, ALCEDIAG and SYNLAB are announcing, on the occasion of the 31st EPA congress, the availability of EDIT-B™, the world’s first CE-marked in-vitro blood test designed to differentiate BD from depression.
EDIT-B™: a reliable, validated and rapid biological response to reduce the diagnostic delay and address an unmet medical need.
ALCEDIAG and SYNLAB are making EDIT-B™ , based on RNA editing and AI, available to specialized healthcare professionals and their patients in Europe.
Clinically validated in two clinical studies on independent cohorts and CE IVD marked, it offers remarkable performance with sensitivity and specificity above 80%. Its objective is to help practitioners make a quicker diagnosis; reducing the diagnostic delay to a few days; patient care being consequently dramatically improved and patient management optimized.
“When the brain malfunctions, it sends signals just as a sick liver would. These signals, or biomarkers, can then be captured by a blood test, based on RNA editing, allowing for a faster diagnosis. The introduction of biology into psychiatry is a revolution”, comments Dr. Dinah Weissmann, co-founder and Scientific Director of ALCEDIAG.
“We are very proud to be part of the EDIT-B project, which will give an answer to so many patients who must face such a difficult patient journey before being diagnosed. The availability of this test will really be a game-changer in the psychiatric area”, states Giovanni Gianolli, CEO of SYNLAB Italy.
EDIT-B™ complements the existing clinical scales. Technically, it measures the RNA editing of specific markers in patients’ blood. ALCEDIAG which developed the test and ensured its regulatory compliance, uses state-of-the-art Next Generation Sequencing (NGS) technology coupled with proprietary algorithms using artificial intelligence (AI).
EDIT-B™ is now available in Italy. It will be soon available in France and Switzerland during 2023 and gradually in other countries (SYNLAB is present 26 countries in Europe).